Cizzle Biotechnology Holdings PLC - London-based company developing a blood test for the early detection of various forms of lung cancer - Inks research and development agreement with biomedical charity St George Street Capital, to develop a companion diagnostic test for autoimmune disease.
The test will look to address unmet clinical needs in a wide variety of diseases. St George Street will pay GBP200,000 upfront when the project starts, with further milestone payments totalling up to GBP1 million.
"We announced on 20 September following SGSC's successful ARCADIA clinical trial, a royalty agreement related to AZD1656. We are now also delighted to sign a new R&D agreement with SGSC to develop a companion diagnostic which has fees payable to Cizzle Biotechnology of up to GBP1 million. This will strengthen the two parties' close relationship through the development of a companion diagnostic test for the use of their therapeutic asset that is aimed at addressing unmet needs in the area of autoimmune disease," says Executive Chair Allan Syms.
Current stock price: 4.34 pence, up 3.3%
Year-to-date change: down 54% since May 14
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.